BN
|
HealthAI Desk•3 views

Stopping GLP-1 Medications Linked to Higher Heart Attack, Stroke, and Death Risk, Study Finds

A study published in BMJ Medicine found that stopping GLP-1 medications such as Ozempic and Wegovy increases cardiovascular risks in Type 2 diabetes patients. Over three years, continuous use reduced risk by 18%, while quitting for six months or two years raised risks by 4% and 22%, respectively. The research highlights that cardiovascular protection accumulates slowly but diminishes rapidly upon discontinuation, a phenomenon described as 'metabolic whiplash.' High discontinuation rates, driven by access issues and side effects, pose a challenge to sustained treatment. The FDA has approved semaglutide for cardiovascular risk reduction in specific populations, and experts stress the importance of long-term therapy to avoid reversing benefits.

Ad slot
Stopping GLP-1 Medications Linked to Higher Heart Attack, Stroke, and Death Risk, Study Finds

A new study from Washington University School of Medicine indicates that discontinuing GLP-1 drugs like Ozempic and Wegovy rapidly increases cardiovascular risks in Type 2 diabetes patients, with protection lost faster than it is built.

Study Shows Sharp Risk Rise After Treatment Gaps

Published in BMJ Medicine, the research tracked over 333,000 adults with Type 2 diabetes for three years using electronic health records. Key findings include:

  • Continuous GLP-1 users reduced cardiovascular risk by 18%.
  • Stopping for six months increased risk by 4% compared to ongoing use.
  • A two-year treatment gap raised risk by 22%.

Mechanism: Rapid Loss of Cardiovascular Protection

Dr. Ziyad Al-Aly, study author and WashU Medicine epidemiologist, stated that GLP-1s provide extensive metabolic benefits beyond weight loss, such as lowering cholesterol, blood pressure, and inflammation. He termed the effect upon stopping as "metabolic whiplash," where gains reverse quickly, noting that protection takes years to build but half the time to undo.

Ad slot

Context: FDA Approval and Established Benefits

The cardiovascular advantages of GLP-1s are recognized; in 2024, the FDA approved semaglutide (in Ozempic and Wegovy) for reducing major cardiovascular events in adults with heart disease and obesity. This study offers large-scale evidence on risks specifically from quitting among diabetes patients.

Challenge: High Discontinuation Rates

Discontinuation rates for GLP-1s range from 36% to 81% due to access barriers and side effects like nausea. The study underscores that long-term adherence is critical to maintain benefits, and addressing these issues is essential for the healthcare system.

Recommendations and Future Outlook

Experts advise that GLP-1 therapy should be considered a long-term commitment. Efforts focus on improving drug access, managing side effects proactively, and developing next-generation treatments with fewer adverse effects. "People need to realize that there's a price of stopping," Al-Aly emphasized.

For tips or story ideas, contact Annika Constantino at [email protected].

Ad slot